Nuvation Bio (NUVB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NUVB · Stock Price

USD 4.81+2.72 (+130.14%)

Market Cap: $1.7B

Historical price data

Market Cap: $1.7BPipeline: 17 drugs (3 Phase 3)Patents: 18Founded: 2018HQ: New York, United States

Sector Ranking#154 in Small Molecule Drugs #33 in Oncology (General)

Overview

Nuvation Bio is a mission-driven oncology company focused on developing next-generation therapies for cancers with high unmet need, aiming to improve efficacy and reduce side effects. A key inflection point was achieved in 2025 as the company transitioned to commercial-stage status, celebrating at the NYSE. Its strategy leverages founder David Hung's proven track record, a hybrid pipeline built on proprietary discovery and strategic acquisitions, and a global operational footprint. The company is now positioned to build a sustainable oncology franchise.

Oncology

Technology Platform

A multi-modal strategy combining a proprietary Drug-Drug Conjugate (DDC) platform for targeted delivery with a scientifically rigorous framework for drug discovery and strategic asset acquisition.

Pipeline

17

17 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Taletrectinib + Placebo	Non-small Cell Lung Cancer (NSCLC)	Phase 3
Taletrectinib + Crizotinib	Non Small Cell Lung Cancer	Phase 3
safusidenib + Placebo	Glioma	Phase 3
AB-106	Solid Tumor	Phase 2
AB-106	Non Small Cell Lung Cancer	Phase 2

Funding History

3

Total raised:$675M

IPO$250MUndisclosedFeb 15, 2021

Series B$150MOmega FundsJul 15, 2020

Series A$275MOmega FundsDec 15, 2018

Opportunities

The transition to commercial-stage with talazoparib provides a foundational revenue stream and de-risks the investment.

The proprietary pipeline, particularly the DDC and selective BET inhibitor, addresses large markets with high unmet need and offers significant upside from clinical catalysts and potential best-in-class profiles.

Risk Factors

Key risks include clinical failure of novel pipeline assets, intense commercial competition for talazoparib from larger pharma, and the ongoing need for substantial capital to fund development, which could lead to shareholder dilution if commercial revenues underperform.

Competitive Landscape

Nuvation Bio faces entrenched competition in the PARP inhibitor market and crowded, innovative fields in BET inhibitors and ADCs/DDCs. Its differentiation lies in the selective design of its novel agents and the proven execution capability of its leadership team, which serves as a significant strategic moat.